31 results match your criteria: "France E.V.B.; and Centre Hospitalier[Affiliation]"
Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients.
Neuro Oncol
March 2015
Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas (E.V.-B., M.R.G.); Department of Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas (K.A., K.W.); Department of Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas (Y.Y., J.W.); Office of Multicenter Clinical Research, The University of Texas M.D. Anderson Cancer Center, Houston, Texas (M.J.N.-R.); Department of Neurosurgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah (H.C.); Division of Hematology-Oncology, Children's Hospital Los Angeles, Los Angeles, California (G.D.); Departments of Neurology and Medicine (Medical Oncology), University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (F.S.L.); Department of Neurosurgery, Assistance Publique-Hopitaux de Marseille, Aix-Marseille University, Marseille, France (P.M.); Departments of Neurology & Neurosurgery, Henry Ford Hospital, Detroit, Michigan (T.M.); Department of Neurology, Memorial-Sloan Kettering Cancer Center, New York, New York (A.O.); Department of Neurology, Stanford University & Lucile Packard Children's Hospital, Palo Alto, California (S.P.); Department of Neuro-Oncology, UCSF Helen Diller Comprehensive Cancer Center, San Francisco, California (M.P.); Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin (H.I.R.); Department of Neuroscience, University San Giovanni Battista Hospital, Turin, Italy (R.S.); Department of Neurosurgery, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina (J.W.); Department of Family Health, School of Nursing, The University of Texas Health Science Center-Houston, Houston, Texas (T.S.A.); CERN Foundation, Dayton, Ohio.
Article Synopsis
- Ependymomas are rare tumors in the central nervous system (CNS), and this study analyzed data from 282 adult patients across 19 institutions to better understand their clinical characteristics and outcomes.
- The research identified significant factors affecting progression-free survival, including tumor location, grade, and surgical resection status; notably, supratentorial tumors and grade III tumors had a higher risk of early progression.
- This ongoing multicenter study aims to enhance the understanding of ependymoma by utilizing a large, clinically annotated dataset, paving the way for improved clinical and translational research.
Clinical outcomes and safety of transfemoral aortic valve implantation under general versus local anesthesia: subanalysis of the French Aortic National CoreValve and Edwards 2 registry.
Circ Cardiovasc Interv
August 2014
From the Centre Hospitalier Universitaire (CHU) Henri Mondor, Creteil, France (A.O., M.Y., G.M., K.C., J.-L.D.-R., E.T.); Centre Hospitalier Universitaire Brest, Brest, France (M.G.); Centre Hospitalier Universitaire Dupuytren, Limoges, France (M. Laskar); Hopital Charles Nicolle, University of Rouen, INSERM Unite 1096, Rouen, France (H.E.); Clinique Pasteur, Toulouse, France (J.F.); Bichat Hospital, Paris, France (B.I.); Insitut Jacques Cartier, Massy, France (P.D.-G.); Pitie-Salpetriere Hospital, Paris, France (P.L.); Centre Hospitalier Universitaire Rennes, Rennes, France (A.L.); Centre Hospitalier Universitaire Lille, Lille, France (A.P., E.V.B.); University Lyon 1, Lyon, France (M. Lievre); Centre Hospitalier Universitaire Besançon, Besançon, France (R.C.); and Department of Hygiene and Public Health, Nippon Medical School, Tokyo, Japan (T.O.).
Background: Transcatheter aortic valve implantation (TAVI) performed under local anesthesia (LA) is becoming increasingly common. We aimed to compare the clinical outcomes in patients who underwent transfemoral-TAVI under general anesthesia (GA) and LA.
Methods And Results: Data from 2326 patients in the French Aortic National CoreValve and Edwards 2 (FRANCE 2) registry who underwent transfemoral-TAVI were analyzed.
Routine pressure wire assessment at time of diagnostic angiography: is it ready for prime time?
Circ Cardiovasc Interv
April 2014
From the Department of Cardiology, University Hospital, Lille, France (E.V.B.); EA2693, Lille-II-University, Lille, France (E.V.B.); Department of Cardiology, Hôpital Louis Pradel, Lyon, France (G.R.); INSERM 1060 CARMEN, Claude Bernard University Lyon 1, Lyon, France (G.R.); and Department of Cardiology, Hopital Privé d'Antony, Antony, France (P.D.).
High on-treatment platelet reactivity as a risk factor for secondary prevention after coronary stent revascularization: A landmark analysis of the ARCTIC study.
Circulation
May 2014
From the ACTION Study Group, Institut de Cardiologie (AP-HP), INSERM UMRS 1166, Université Paris 6, Paris, France (G.M., J.S., O.B., P.S., S.A.O., M.K., J.-P.C.); Hôpital Louis Pasteur, Le Coudray, France (G.R.); Hôpital de la Timone, Marseille, France (J.-L.B., T.C.); CH de Bastia, Bastia, France (Z.B.); CHU Carémeau, Nîmes, France (G.C.); CH de la Région Annecienne, Annecy, France (L.B.); Hôpital Cardiologique, Lille, France (E.V.B.); CH de Lagny, Marne-la-Vallée, France (S.E.); Clinique Sainte-Clothilde, La Réunion, France (C.P.); Hôpital Lariboisière, Paris, France (P.H.); CHU Clermont-Ferrand, Clermont-Ferrand, France (P.M.); Hôpital de Rangueil, Toulouse, France (D.C.); Unite de Recherche Clinique, Hôpital Lariboisière, ACTION Study Group, Paris, France (H.R., E.V.); Hôpital Bichat, Paris, France (P.A.); HIA du Val-du-Grâce, Paris, France (J.M.); Hôpital Bichat, ACTION Study Group, Paris, France (J.A.); Hôpital Trousseau, Chambray-lès-Tours, ACTION Study Group, Paris, France (C.S.-E.); and CHU Côte de Nacre, Caen, ACTION Study Group, Caen, France (F.B.).
Background: Individualizing antiplatelet therapy after platelet function testing did not improve outcome after coronary stenting in the Assessment by a Double Randomization of a Conventional Antiplatelet Strategy Versus a Monitoring-Guided Strategy for Drug-Eluting Stent Implantation and of Treatment Interruption Versus Continuation One Year After Stenting (ARCTIC) study. Whether results are different during the phase of secondary prevention starting after hospital discharge, when periprocedural events have been excluded, is unknown.
Methods And Results: In ARCTIC, 2440 patients were randomized before coronary stenting to a strategy of platelet function monitoring (VerifyNow P2Y12/aspirin point-of-care assay) with drug adjustment in suboptimal responders to antiplatelet therapy or to a conventional strategy without monitoring and without drug or dose changes.
Postprocedural aortic regurgitation in balloon-expandable and self-expandable transcatheter aortic valve replacement procedures: analysis of predictors and impact on long-term mortality: insights from the FRANCE2 Registry.
Circulation
April 2014
Department of Cardiology, University Hospital, Lille, France (E.V.B., F.J., A.V., C.B., J.-L.A., C.D., A.P.); EA2693, Lille-II-University, Lille, France (E.V.B., F.J., S.S., A.V., C.B., J.-L.A., C.D., A.P.); INSERM-U744, Lille, France (J.D.); CHU Bichat, Paris, France (B.I.); CHU Rouen, Rouen, France (H.E.); CHU Dupuytren, Limoges, France (M. Laskar); CHU Pitié-Salpêtrière, Paris, France (P.L.); University Lyon-1, Lyon, France (M. Lievre; Institut cardiovasculaire Paris-Sud, Paris, France (P.D.-G.); URC-ECO, Paris, France (K.C.); Clinique Pasteur, Toulouse, France (J.F.); CHU Rennes, Rennes, France (A.L.); CHU Brest, Brest, France (M.G.); and CHU Mondor Créteil, Créteil, France (E.T.).
Background: Significant postprocedural aortic regurgitation (AR) is observed in 10% to 20% of cases after transcatheter aortic valve replacement (TAVR). The prognostic value and the predictors of such a complication in balloon-expandable (BE) and self-expandable (SE) TAVR remain unclear.
Methods And Results: TAVR was performed in 3195 consecutive patients at 34 hospitals.
Outcome impact of coronary revascularization strategy reclassification with fractional flow reserve at time of diagnostic angiography: insights from a large French multicenter fractional flow reserve registry.
Circulation
January 2014
Departments of Cardiology, University Hospital (E.V.B.); EA2693, Lille-II-University (E.V.B.); Hôpital Louis Pradel, Lyon (G.R.); INSERM 1060 CARMEN, Claude Bernard University Lyon1 (G.R,); Clinique Sainte Clotilde, Saint Denis de la Réunion (C.P., K.B.); CHU La Timone, Marseille (T.C.); CHU Mondor, Créteil (E.T., S.C.); CH d'Annecy, Annecy (L.B.); C.H.I.T.S. Hôpital Sainte Musse, Toulon (D.B.); Centre Hospitalier Haguenau, Haguenau (M.H.); Hôpital de la Croix-Rousse, Lyon (C.B., R.D.); Institut Pasteur de Lille-INSERM (J.D.), Université Pierre et Marie Curie - Paris 6 (Y.E.H.), Hôpital lariboisière (G.S.), Paris; Centre Hospitalier Valence, Valence (C.B.); Hôpital Albert Schweizer, Colmar (N.L.); Centre Hospitalier La Durance, Avignon (P.B.); Centre Hospitalier Amiens Sud, Amiens (L.L.); and Hopital Privé d'Antony, Antony, France (P.D.).
Background: There is no large report of the impact of fractional flow reserve (FFR) on the reclassification of the coronary revascularization strategy on individual patients referred for diagnostic angiography.
Methods And Results: The Registre Français de la FFR (R3F) investigated 1075 consecutive patients undergoing diagnostic angiography including an FFR investigation at 20 French centers. Investigators were asked to define prospectively their revascularization strategy a priori based on angiography before performing the FFR.